| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
Stevioside targets multiple pathways: it potentiates insulin secretion, increases insulin sensitivity, and enhances acetyl-CoA carboxylase (ACC) gene expression. It acts as a Ca2+ influx inhibitor and has immunomodulatory activity, increasing phagocytic activity, haemagglutination antibody titre, and delayed type hypersensitivity.
|
|---|---|
| ln Vitro |
In vitro, stevioside exhibits antioxidant, anti-inflammatory, and anticancer activities. It potentiates insulin secretion and enhances ACC gene expression. It increases insulin sensitivity and acts as a Ca2+ influx inhibitor. It has immunomodulatory effects, including increased phagocytic activity. Cell viability assays have been used to evaluate its effects.
|
| ln Vivo |
In vivo, stevioside can reduce postprandial blood glucose levels in type 2 diabetic patients, indicating beneficial effects on glucose metabolism. It has antihypertensive and antihyperglycemic effects. It has anti-inflammatory effects against dextran sulfate sodium-induced ulcerative colitis in mice and protects against rhabdomyolysis-induced acute kidney injury via PPAR-γ agonism in rats.
|
| Enzyme Assay |
General protocols for glucose metabolism assays use pancreatic beta-cells or intestinal epithelial cells. Cells are treated with stevioside (10-1000 µM) for 1-24 hours. Insulin secretion is measured by ELISA. Glucose uptake is assessed using 2-NBDG or [3H]-2-deoxyglucose. ACC gene expression is quantified by RT-qPCR. Intracellular calcium levels are measured using Fluo-4 or Fura-2 imaging.
|
| Cell Assay |
General protocols for cell viability and anticancer assays use various cancer cell lines (e.g., HeLa, MCF-7). Cells are seeded in 96-well plates and treated with stevioside at various concentrations (1-500 µM) for 24-72 hours. Cell viability is assessed by MTT or CCK-8 assays. Apoptosis is evaluated by caspase-3/7 activity or Annexin V/PI staining. IC50 values are calculated from dose-response curves. Positive controls (e.g., doxorubicin) and negative controls (vehicle only) are included.
|
| Animal Protocol |
General protocols for in vivo antihyperglycemic studies use diabetic animal models (e.g., streptozotocin-induced diabetic rats or db/db mice). Stevioside is administered orally at doses of 50-500 mg/kg daily for 2-4 weeks. Fasting blood glucose, postprandial glucose, and HbA1c levels are measured. Oral glucose tolerance tests (OGTT) are performed. Serum insulin levels are measured by ELISA. Pancreatic tissues are collected for histological analysis. Body weight and food intake are monitored.
|
| ADME/Pharmacokinetics |
Stevioside has a molecular weight of 804.87 g/mol (C38H60O18). It is a diterpenoid glycoside that is orally active. It is a natural sweetener isolated from Stevia rebaudiana. It is slightly soluble in water and soluble in ethanol. Following oral administration, it is metabolized by intestinal microbiota to steviol, which is absorbed and excreted via the kidneys. Stevioside has a favorable pharmacokinetic profile with a long duration of action.
|
| Toxicity/Toxicokinetics |
Stevioside is generally recognized as safe (GRAS) as a food additive and natural sweetener. It has a favorable safety profile with no significant toxicity at typical consumption levels. High doses may cause gastrointestinal discomfort. It has been extensively studied for safety and is approved as a food additive in many countries. No significant adverse effects have been reported at recommended intake levels.
|
| References | |
| Additional Infomation |
Stevioside is a diterpenoid glycoside, a derivative of steviol glycoside, in which the hydroxyl group at the 2-position of allyl β-D-glucoside is converted to the corresponding β-D-glucoside. It is a natural herbal sweetener, 250-300 times sweeter than sucrose (but slightly bitter), extracted from stevia rebaudiana, native to South America. It has multiple functions, including as a sweetener, antioxidant, antitumor agent, hypoglycemic agent, anti-inflammatory agent, and plant metabolite. It is a diterpenoid glycoside, ent-kaurane diterpenoid, β-D-glucoside, tetracyclic diterpenoid, and bridging compound. Functionally, it is related to steviol and steviol glycosides. Stevioside has been reported in cattle, plants in the Asteraceae family, and stevia rebaudiana, with relevant data available. See also: Stevia rebaudiana leaves (partial).
Stevioside (CAS 57817-89-7) is a natural diterpenoid glycoside sweetener from Stevia rebaudiana with antihypertensive, antihyperglycemic, antioxidant, anti-inflammatory, and anti-tumor activities. It potentiates insulin secretion and increases insulin sensitivity. It is approved as a food additive and sweetener in many countries. It has not been approved as a pharmaceutical drug. |
| Molecular Formula |
C38H60O18
|
|---|---|
| Molecular Weight |
804.8722
|
| Exact Mass |
804.377
|
| CAS # |
57817-89-7
|
| PubChem CID |
442089
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
963.3±65.0 °C at 760 mmHg
|
| Melting Point |
198°C
|
| Flash Point |
290.3±27.8 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.646
|
| LogP |
1.19
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
56
|
| Complexity |
1450
|
| Defined Atom Stereocenter Count |
21
|
| SMILES |
O([C@]1([H])[C@@]([H])([C@]([H])(C([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])O[H])O[C@@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])O[H])O[H])[C@]12C(=C([H])[H])C([H])([H])[C@]3(C([H])([H])C([H])([H])C4([H])[C@@](C(=O)O[C@@]5([H])C([H])([C@]([H])(C([H])([C@@]([H])(C([H])([H])O[H])O5)O[H])O[H])O[H])(C([H])([H])[H])C([H])([H])C([H])([H])C([H])([H])[C@@]4(C([H])([H])[H])C3([H])C([H])([H])C1([H])[H])C2([H])[H]
|
| InChi Key |
UEDUENGHJMELGK-HYDKPPNVSA-N
|
| InChi Code |
InChI=1S/C38H60O18/c1-16-11-37-9-5-20-35(2,7-4-8-36(20,3)34(50)55-32-29(49)26(46)23(43)18(13-40)52-32)21(37)6-10-38(16,15-37)56-33-30(27(47)24(44)19(14-41)53-33)54-31-28(48)25(45)22(42)17(12-39)51-31/h17-33,39-49H,1,4-15H2,2-3H3/t17-,18-,19-,20+,21+,22-,23-,24-,25+,26+,27+,28-,29-,30-,31+,32+,33+,35-,36-,37-,38+/m1/s1
|
| Chemical Name |
[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1R,4S,5R,9S,10R,13S)-13-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-5,9-dimethyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~310.61 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.58 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.58 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (2.58 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2424 mL | 6.2122 mL | 12.4244 mL | |
| 5 mM | 0.2485 mL | 1.2424 mL | 2.4849 mL | |
| 10 mM | 0.1242 mL | 0.6212 mL | 1.2424 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05852145 | NOT YET RECRUITING | Drug: Stevioside | Dental Plaque Microbiome pH |
Hospital Infantil de Mexico Federico Gomez | 2023-10 | Phase 1 Phase 2 |
| NCT01488383 | WITHDRAWN | Drug: Purified extract of Rebaudina Stevia-Stevioside Drug: Sodium saccharin |
Hyperglycemia Hypertension |
Basque Health Service | 2013-09 | Not Applicable |
| NCT01757990 | COMPLETED | Dietary Supplement: Effect of Stevioside and Rebaudioside on plaque pH | Dental Caries | Università degli Studi di Sassari | 2012-03 | Phase 2 |
| NCT02834715 | COMPLETED | Dietary Supplement: Stevia rebaudiana liquid extract | Diabetes Mellitus | Yaounde Central Hospital | 2016-03 | Not Applicable |
| NCT03993418 | COMPLETED | Dietary Supplement: stevia | Glucose Intolerance Obesity |
University of Manchester | 2019-02-01 | Not Applicable |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
